Xenon Pharmaceuticals Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026New stock plans affect how employees get paid and can dilute existing shareholders' ownership over time.
Quarterly earnings reports show if a company is making money and growing or losing ground.
Earnings announcements help investors understand company performance and decide if stock is a good investment.
More shares for employee compensation means more potential dilution to your ownership stake.
Annual meetings let shareholders vote on important company decisions like board members and compensation.
New money raised funds research and operations, but new shares dilute existing investors' ownership percentage.
Legal document details the stock offering terms, helping investors understand what was sold and at what price.
Stocky reads Xenon Pharmaceuticals Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Xenon Pharmaceuticals Inc.'s most recent tracked filing was a 8-K on 3 Jun 2026: Shareholders approve 2026 equity incentive plan replacing 2014 plan.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.